Heart Failure Clinical Trial
Official title:
Frequency and Magnitude of Sub-clinical Systolic Dysfunction by Strain Imaging in Heart Failure With Preserved Ejection Fraction
Background: Originally thought to be purely due to LV diastolic dysfunction, studies in
western countries have suggested that heart failure with preserved ejection fraction (HFpEF)
is more complex. In patients with HFpEF, LV systolic function is commonly considered normal
as the global ejection fraction (EF) is normal. However, the EF reflects only the global
cardiac contractile function and does not take the subclinical systolic function into
consideration. Therefore more attention should be paid on this subset of heart failure
population in which the frequency and magnitude of concomitant subclinical systolic
dysfunction has not been clearly defined.
Objective: The principal objective of this study was to assess the global longitudinal
systolic function of the LV in patients with HFpEF in a tertiary level hospital with the aim
of finding out the frequency and magnitude of impaired subclinical systolic dysfunction by
using Global Longitudinal Strain (GLS) derived from 2D speckle tracking echocardiography and
to see if there is any correlation of GLS with New York Heart Association (NYHA) functional
class and BNP level in these patients.
Methods: This was a cross-sectional study conducted from May 2018 to April 2019. A total of
31 patients with HFpEF (Group I) and 31 healthy volunteers of similar age and sex (Group II)
were enrolled in the study by consecutive sampling. Detailed history including NYHA
functional class, physical examination, relevant investigations including BNP level was done
in patients with HFpEF. 2D echocardiography, color Doppler, tissue Doppler and 2D speckle
tracking echocardiography was done in both groups. GLS was obtained in a total of 31 patients
with HFpEF (Group I), diagnosed according to the 2016 European Society of Cardiology (ESC)
guidelines for the diagnosis and treatment of acute and chronic heart failure and compared
with GLS of 31 healthy volunteers (Group II), to find out the frequency and magnitude of
impaired subclinical systolic function in patients with HFpEF. GLS was also compared with
their NYHA functional class and BNP level to find out if any significant relationship is
present.
Result: All patients with HFpEF had preserved LV ejection fraction (LVEF>50%) and evidence of
diastolic dysfunction. HFpEF patients demonstrated significantly lower GLS compared to
healthy controls (14.92 ± 3.16 versus 20.60 ± 1.84). The reduction in LV GLS was
statistically significant (p <0.001). Majority of patients with HFpEF (74.2%) had reduced
GLS, when reduced GLS was defined as > 2SD below the mean value for healthy volunteers,
indicating the presence of subclinical systolic dysfunction in majority of these patients.
Worse GLS was associated with higher BNP levels in patients with HFpEF when modeled
categorically as quartiles (p = 0.044) and also when modeled continuously (Pearson
correlation, r = 0.5, p = 0.004), there was negligible correlation between LV GLS and NYHA
symptom class when modeled continuously (Spearman's correlation, rs = 0.052, p = 0.789).
Conclusion: Strain imaging detects impaired systolic function despite preserved global EF in
patients with HFpEF. Subclinical systolic dysfunction was frequent in the majority of HFpEF
patients. Lower LV GLS is associated with higher BNP level. LV GLS was not associated with
NYHA functional class. Further large scale studies are recommended to confirm the findings of
this study.
Case: All patients presented with the diagnosis of heart failure with preserved ejection
fraction (HFpEF) to Department of Cardiology, BSMMU were initially approached and then
selected as case on the basis of inclusion and exclusion criteria. Heart failure diagnosis
was made according to the 2016 ESC Guidelines for the diagnosis and treatment of acute and
chronic heart failure. All inclusion criteria were established within 24 hours of
presentation. The eligible patients were explained about the study, written informed consent
was taken and demographic data were recorded.
Control group: Apparently normal healthy volunteers were initially approached. Medical
records were reviewed for prevalent cardiovascular disease (stroke, coronary artery disease,
heart failure, arrhythmia), cardiovascular risk factors (hypertension, diabetes mellitus,
hyperlipidemia, smoking, renal dysfunction), systemic disease (such as cancer, infections,
autoimmune disorders) or any pharmacotherapy Subjects were excluded if any of these were
identified. The eligible patients were explained about the study. Written informed consent
was taken and demographic data, Pulse, blood pressure and respiratory rate were recorded.
Clinical data, including detailed medical history, cardiovascular risk factors and associated
comorbidities of patients with HFpEF were noted. Relevant physical examination was done and
recorded in semi-structured designed data collection sheet. Complementary data were collected
including chest radiography, ECG, Echocardiography, and relevant laboratory tests. The
symptoms of patients were noted. Shortness of breath was graded according to NYHA functional
classification. Venous blood samples were collected in plastic vacuum tubes at room
temperature for analysis of BNP using chemilumunescent micro particle immunoassay (CMIA) on
the ARCHITECT iSystem, on day 1 of presentation in HFpEF cases. Other laboratory
investigations including hemoglobin, serum creatinine, HbA1c in diabetics were also done.
Echocardiography was performed by using Vivid E9 (GE Healthcare, Norway) using a 3.5 Mhz
transducer. ECG leads were connected before analysis. LV diameters were calculated by M-mode
and LVEF by Simpson‟s modified biplane method. The LV mass was estimated by using the area
length method and adjusted for body surface area. Echocardiographic LV hypertrophy was
defined as an LV mass index> 115 g/m2 for men and > 95 g/m2 for women. LV geometry was
classified based on relative wall thickness (RWT), defined as (2×diastolic posterior wall
thickness)/LV end-diastolic dimension and Left Ventricular Mass Index (LVMi) as recommended
by the American Society of Echocardiography (ASE): normal = RWT ≤ 0.42 and no LVH; eccentric
hypertrophy = RWT ≤ 0.42 and LVH; concentric remodeling = RWT > 0.42 and no LVH; concentric
hypertrophy = RWT > 0.42 and LVH. Right ventricular (RV) function was assessed by tricuspid
annular plane systolic excursion (TAPSE) and tricuspid lateral annular systolic velocity (S')
by pulsed tissue Doppler. Peak pulmonary arterial systolic pressure (PASP) was estimated as
the sum of peak RV-right atrial gradient from the tricuspid valve regurgitant jet and right
atrial pressure on the basis of size and collapsibility of inferior vena cava. Presence and
severity of valvular heart diseases were assessed by color Doppler imaging and image guided
pulsed and continuous Doppler studies according to 2014 AHA/ACC Guidelines for the Management
of Patients with Valvular Heart Disease. Patients with more than mild valvular heart diseases
were excluded.Diastolic function parameters were measured as follows: peak early diastolic
filling (E) and late diastolic filling (A) velocities, E/A ratio, E deceleration time, early
diastolic septal and lateral mitral annular velocity (e'), average E/E', peak TR jet
velocity, left atrial volume index. Left atrial volume index was calculated using biplane
area-length method from apical four and two chamber views at end-systole from the frame
preceding mitral valve opening and was indexed to body surface area. Diastolic dysfunction
was classified into three grades according to 2016 ASE/EACVI guidelines.
LV longitudinal strains were analyzed by 2D speckle tracking echocardiography for both
controls and patients with HFpEF. Cardiac cycles were obtained during a breath hold in
end-expiration. Special care was taken to obtain correct view and checking for
foreshortening. Endocardial border was traced at end systole, with a frame rate of
50-80/second, from apical long axis, four chambers and two-chambers view. In case of poor
tracking, region of interest (ROI) was readjusted. The results of all three planes were
combined in a single bull‟s eye summary, along with a global longitudinal strain value (GLS)
for the LV which was automatically calculated by automated function imaging (AFI). All strain
analysis on HFpEF, and normal control subjects was be performed by a single investigator. Two
independent investigators analyzed the echocardiography recordings blinded to clinical data.
The intra-observer and inter-observer variability of GLS was assessed from 10 randomly
selected patients by intra-class correlation coefficient(R). The R value for intra-observer
variability was 0.983 and for inter-observer variability was 0.980. This showed good
reproducibility of GLS for both same and different operators.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|